Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:29 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 1,709 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infection (HIV) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

NCT02716675
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01, Placebo for VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
2,699 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Nov 3, 2026, 6:29 AM EST
Completed Not applicable Interventional

Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms

NCT00000707
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Nov 3, 2026, 6:29 AM EST
Completed Not applicable Interventional Results available

Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV

NCT01946139
View directory record Official record
Conditions
Anal Cancer, HIV Infection, Human Papilloma Virus Infection
Interventions
comparison of screening methods, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
Procedure · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Nov 3, 2026, 6:29 AM EST
Not listed Early Phase 1 Interventional

Pharmacokinetics Distribution of Raltegravir by PET/MR

NCT03174977
View directory record Official record
Conditions
HIV-1-infection
Interventions
18F-Raltegravir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Nov 3, 2026, 6:29 AM EST
Completed Not applicable Interventional Results available

Integration of Hypertension Management Into HIV Care in Nigeria

NCT04704336
View directory record Official record
Conditions
Human Immunodeficiency Virus, Hypertension
Interventions
Task-shifting strategy for HTN control (TASSH) protocol
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

NCT05393271
View directory record Official record
Conditions
HIV Infections
Interventions
VH4011499, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 1 Interventional

The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis

NCT00002316
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Lobradimil, Amphotericin B
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 4 Interventional Results available

Anti-HIV Medications for People Recently Infected With HIV

NCT00106171
View directory record Official record
Conditions
HIV Infections
Interventions
Highly active antiretroviral therapy (HAART)
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

NCT02165267
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01, SC placebo for VRC01, IV placebo for VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 2 Interventional

Relaxation Response With Acupuncture for HIV Patients

NCT00064740
View directory record Official record
Conditions
Human Immunodeficiency Virus, AIDS
Interventions
relaxation response
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects

NCT00334659
View directory record Official record
Conditions
HIV Infections
Interventions
apricitabine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Nov 3, 2026, 6:29 AM EST
Terminated Phase 1 Interventional

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

NCT02109224
View directory record Official record
Conditions
Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, HIV Infection, Intraocular Lymphoma, Multicentric Angiofollicular Lymphoid Hyperplasia, Nodal Marginal Zone Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Plasma Cell Myeloma, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 3 Interventional Results available

Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

NCT00358917
View directory record Official record
Conditions
Human Immunodeficiency Virus Infections
Interventions
lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 2 Interventional Results available

Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)

NCT01228318
View directory record Official record
Conditions
HIV Infection, Bone Loss, Osteopenia, Osteoporosis
Interventions
Zoledronic acid
Drug
Lead sponsor
Emory University
Other
Eligibility
30 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Nov 3, 2026, 6:29 AM EST
Completed No phase listed Observational

Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension

NCT00845013
View directory record Official record
Conditions
HIV Infection, Pulmonary Hypertension, Endothelial Function, HIV Infections
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Nov 3, 2026, 6:29 AM EST
Completed Not applicable Interventional

TechMPower: Advancing HIV/SUD Care and Service Delivery for People in Re-entry

NCT07088770
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Substance Abuse Disorder
Interventions
Community Coalition CLS Workgroup/Network of Providers, Tech-mediated Training and Service Delivery, Multidisciplinary Implementation Team with Champion, Tech-mediated Peer Navigation Enhanced Case management (NCM)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kingston, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 2 Interventional

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

NCT00002423
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 3 Interventional

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

NCT00234910
View directory record Official record
Conditions
HIV Infection
Interventions
Tenofovir DF, lopinavir/ritonavir with 2 Nucleoside RTIs
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2008 · Synced Nov 3, 2026, 6:29 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)

NCT01161446
View directory record Official record
Conditions
HIV
Interventions
Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
Behavioral · Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Nov 3, 2026, 6:29 AM EST
Completed No phase listed Observational

Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)

NCT00244803
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Nov 3, 2026, 6:29 AM EST
Recruiting Not applicable Interventional

The Role of the Gastrointestinal-associated Lymphoid Tissue in the Cure of HIV Infection

NCT05652088
View directory record Official record
Conditions
HIV Infection
Interventions
Colonoscopy
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 1 Interventional

Interaction With HIV Antiretroviral Agents

NCT02556268
View directory record Official record
Conditions
HIV-DDI
Interventions
Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Nov 3, 2026, 6:29 AM EST
Completed Phase 2 Interventional Results available

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00078403
View directory record Official record
Conditions
HIV Infections, Hepatitis C, Liver Disease
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Nov 3, 2026, 6:29 AM EST
Active, not recruiting Phase 2 Interventional

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

NCT03519464
View directory record Official record
Conditions
Idiopathic CD4 T Cell Lymphocytopenia
Interventions
Gardasil 9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 6:29 AM EST